Foghorn Therapeutics Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 7, 2024. This summary uses full-year results because the filing does not provide a clear standalone Q4 income statement. Foghorn is a clinical-stage biotechnology company developing medicines that target the chromatin regulatory system. It has no approved products and has not generated product-sales revenue.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Collaboration revenue | $34.2 million | $19.2 million |
| Research and development expense | $109.7 million | $105.6 million |
| General and administrative expense | $32.4 million | $30.7 million |
| Operating loss | $107.9 million | $117.1 million |
| Net loss | $98.4 million | $108.9 million |
| Net loss per share, basic and diluted | $2.34 | $2.62 |
| Operating cash flow | $(118.1) million | $193.6 million |
At year-end, cash, cash equivalents and marketable securities totaled $234.1 million, including $80.3 million of cash and equivalents and $153.7 million of marketable securities. Management expects these resources to fund operating and capital needs for at least 12 months from the financial-statement issuance date, while cautioning that estimates may prove inaccurate. Accumulated deficit was $471.6 million. Total liabilities were $363.1 million, including $45.1 million of operating lease liabilities and $302.7 million of deferred revenue; the filing does not report borrowings on the balance sheet. Stockholders’ equity was negative $77.2 million.
There is no gross margin measure given for product sales, as the company has no products on the market. Interest income was $10.9 million, up from $5.7 million. The 2023 income-tax provision was $4.2 million, primarily related to tax treatment of the Lilly upfront payment and required capitalization of research and development costs.
Material changes versus 2022
- Net loss narrowed by $10.5 million, despite operating expenses rising by $5.7 million. Higher collaboration revenue and interest income contributed to the improvement.
- 2023 collaboration revenue included $16.1 million of Merck deferred revenue recognized after Merck terminated its collaboration, effective November 7, 2023. This is an unusual, non-recurring contribution; no material Merck obligations remained.
- Operating cash flow shifted from a $193.6 million inflow in 2022 to a $118.1 million outflow in 2023. The 2022 inflow reflected collection of the $300 million Lilly collaboration receivable, rather than recurring operating cash generation.
- R&D expense rose 3.9% to $109.7 million. Increased platform and early-stage research costs and personnel expense more than offset lower FHD-286 and FHD-609 program spending following clinical holds and study shutdowns.
- Cash and marketable securities declined from $345.8 million at year-end 2022 to $234.1 million at year-end 2023. The company reported $16.2 million of stock-based compensation in 2023.
Outlook, developments and key risks
- FHD-286 is in a Phase 1 combination dose-escalation study in relapsed or refractory AML, with decitabine or cytarabine. The company expects initial combination-study data in the second half of 2024. Its prior monotherapy study was placed on full FDA clinical hold in August 2022 over potential differentiation syndrome and possible links to serious safety events; the hold was lifted in June 2023. An expert panel adjudicated differentiation syndrome in 6 of 40 patients, with none contributing to a patient’s death.
- FHD-909 was selected by Lilly for clinical development in February 2024; Lilly anticipated filing an IND in Q2 2024. Lilly leads development of the partnered program, limiting Foghorn’s unilateral control over timelines and decisions.
- Foghorn reports more than 10 programs and aims to file six INDs over four years. Most programs remain preclinical; development, regulatory approval and commercial success are uncertain.
- FHD-609 development was discontinued after a partial clinical hold; the company decided in April 2023 not to pursue an independent Phase 1 dose-expansion study. The FHD-286 uveal melanoma study was also shut down beginning in Q2 2023.
- The Lilly collaboration has a 50/50 U.S. economics structure for specified joint programs, subject to contractual terms, and potential milestones and ex-U.S. royalties. The remaining $302.7 million of transaction price is expected to be recognized through 2029 or later, depending on activity; recognition is not expected to be even across periods. Revenue estimates depend on significant cost and timing assumptions.
- Principal risks include clinical safety or efficacy failures, further holds or delays, the need for additional capital, dependence on Lilly and external research and manufacturing vendors, competition, and uncertain patent and trade-secret protection. The company expects continuing losses and requires additional funding beyond its stated 12-month liquidity estimate.
Important facts for investors to verify
- FHD-286’s combination-trial enrollment, safety findings and timing of the anticipated second-half 2024 data.
- Whether Lilly files the FHD-909 IND on the anticipated Q2 2024 timeline and how control, cost-sharing and economics operate under the collaboration.
- The cash-burn rate and assumptions supporting management’s at-least-12-month runway estimate, including potential financing needs.
- How much future reported collaboration revenue reflects performance under Lilly versus one-time or non-recurring items, including the Merck termination recognition.
- Clinical status of FHD-609 and other programs, and any new safety, regulatory, manufacturing or intellectual-property developments.